Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment.
Fusco
Vittorio
V
Loidoris
Anastasios
A
Colella
Giuseppe
G
Vescovi
Paolo
P
Campisi
Giuseppina
G
D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007568:Jaw / Q000473:pathology*; D010020:Osteonecrosis / Q000139:chemically induced*; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid